ArticleBMC geriatrics2026
Healthcare professionals' perspectives on prescribing DOACs to frail older patients; the DOAC-FRAIL questionnaire.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating Anticoagulation Decisions in Atrial Fibrillation and Frailty Comorbidity.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDOACs are increasingly prescribed for atrial fibrillation and venous thromboembolism due to their ease of use and lack of monitoring requirements. Prescribing DOACs to frail older patients remains challenging due to higher bleeding and thrombo-embolic risks, comorbidities, polypharmacy, and underrepresentation in clinical trials. This study explored prescribing behavior of healthcare professionals (HCPs) in this complex clinical context.
methodsAn online questionnaire was distributed to HCPs involved in the care of frail older patients. The survey consisted of 27 items divided into three sections: demographics, factors influencing anticoagulant choice, and DOAC management. Descriptive statistics were used to evaluate outcomes.
results355 HCPs completed the questionnaire. HCPs considered frailty(56.9%), fall risk(47.1%) and cognitive impairment (40.0%) when choosing an anticoagulant. Apixaban was the preferred DOAC(56.6%). 74.9% of HCPs did not measure DOAC plasma levels in clinically stable patients, whereas 62.8% measured DOAC plasma level during acute hospitalizations. A large group of HCPs(46.4%) actively switched from VKA to DOAC, but expressed reservations due to fear for an increased bleeding risk. Almost half(48.1%) of HCPs indicated the need for clearer, tailored guidelines for DOAC use in frail older patients.
conclusionsThis study highlights the complexity of prescribing DOACs to frail older patients. While HCPs take multiple factors into account, a standardized approach to prescribing DOACs in this population remains lacking. In addition, almost half of HCPs expressed a need for guidelines regarding DOAC use in frail older patients. Hence, more research is needed to fill this knowledge gap and guide HCPs in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.